Even though, the disclosure of HIV sero- status to sexual partners, friends or relatives is the main tool for prevention and care strategies, most of the HIV/AIDS patients do not inform their close friends. The most common reasons for not disclosure of their status to the community were majorly fear of social rejection and discriminations. Therefore, this study assessed the HIV positive sero-status disclosure and its determinants among People Living with HIV /AIDS (PLWH/A) followed by the Antiretroviral therapy (ART) Clinic in Jimma University Specialized Hospital, Southwest Ethiopia.
A facility based cross-sectional study design was used among 351 ART patients that selected by systematic random sampling from ART clinic of Jimma University Specialized Hospital in March-2014. Data were collected through interviewer-administered questionnaires and analyzed using SPSS version 20.0 software. In a descriptive analysis frequency, mean and percentage were calculated. Bivariate and multivariate analyses were used to identify associated factors and the association between the explanatory and dependent variables was estimated.
Only 37.6% (n = 132) were revealed their HIV positive status to anyone. Disclosure was done towards the sexual partners (88.6%), close family (72.7%) and a larger population (18.2%). Age ≤ 39 years (AOR = 0.014 [95%, CI = 0.005, 0.037]),Male sex (AOR = 3.039, [95% CI = 1.164, 7.935]), WHO stage III – IV at ART start(AOR = 2.766, [95%, CI = 1.321, 5.791]), presence of comorbidity (AOR = 2.500, [95%, CI = 1.483, 4.214]), having any clinical symptoms for HIV(AOR = 2.98, [95%, CI = 1.724, 5.152]),Low physical domain related quality of life (AOR = 3.83, [95%, CI = 2.008, 7.315]) and high social domain related quality of life (AOR = 0.053, [95%, CI = 0.022, 0.125]) were statistically significant association with their HIV sero-status disclosure.
Findings of this study indicated, the disclosure of HIV status is very low. Discloser is more likely when the patient is older, male, and has a higher level of education. Clinical determinants for disclosure was the WHO stage III-IV, treatment duration of ≥2 years, comorbidity, presence of clinical symptoms for HIV, low physical domain related quality of life, low social domain related quality of life and low overall quality of life.